Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (Cadonilimab) in combination with…
- Trial name
- NCT06356688
- Testing
- Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Jing
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine whether participants with platinum-resistant squamous cell carcinoma of the head and neck (SCCHN) who receive either E7050 administered with cetuximab or cetuximab alone experience…
- Trial name
- NCT01332266
- Testing
- E7050, Cetuximab
- Where
- 23 sites in United States, South Korea and 2 more
- Volunteers
- 95 people
- Sponsor
- Eisai Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Squamous Cell
Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
The purpose of this study is to compare the safety and efficacy of Proxinium plus best supportive care with best supportive care only for patients with squamous cell head and neck cancer.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell, Head and Neck Neoplasms
- Trial name
- NCT00412776
- Testing
- Proxinium
- Where
- 122 sites in Argentina, Brazil and 16 more
- Volunteers
- 165 people
- Sponsor
- Sesen Bio, Inc.
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
The purpose of this study was to determine whether LI administered in combination with cyclophosphamide, indomethacin and zinc in a multivitamin (CIZ) combination prior to standard of care therapy (surgery followed by…
- Trial name
- IT-MATTERS (NCT01265849)
- Testing
- LI, Cyclophosphamide, Indomethacin
- Where
- 102 sites in United States, Austria and 21 more
- Volunteers
- 928 people
- Sponsor
- CEL-SCI Corporation
Head and Neck Squamous Cell Carcinoma
Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to evaluate the efficacy and safety of Afatinib in maintenance therapy after post-operative radiochemotherapy (66 Gy and Cisplatin at the dose of 100mg/m2 every 3 weeks)in squamous cell carcinoma of…
- Trial name
- BIBW2992ORL (NCT01427478)
- Testing
- AFATINIB
- Where
- 26 sites in France
- Volunteers
- 134 people
- Sponsor
- Centre Leon Berard
Esophageal Cancer, Squamous Cell, Cetuximab Effect
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
This is an open-label, randomized, controlled trial. At the end of a 28-day screening period, all eligible subjects will be randomly assigned into treatment Arm A or B in a 1:1 ratio.
- Conditions
- Esophageal Cancer, Squamous Cell, Cetuximab Effect, Chemotherapy Effect
- Trial name
- NCT03126708
- Testing
- cetuximab, cisplatin plus paclitaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University
Biliary Tract Neoplasms, Gastric Cancer
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and…
- Conditions
- Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- VISIONARY (NCT04584008)
- Testing
- FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al., Other Therapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
This phase I trial studies the side effects of image-guided hyper-fractioned proton therapy in treating patients with head and neck cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed…
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04870840
- Testing
- Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV
Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal Squamous Cell Carcinoma
The purpose of this research study is to investigate the relationship between vascular habitats and treatment response AND to investigate the potential utility of dynamic contrast enhanced (DCE)-MRI derived parameters in…
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OPSCC (NCT07797738)
- Testing
- MRI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma
[18F]-AraG PET Imaging in LA HNSCC
This study will use [18F]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for…
- Trial name
- NCT07168785
- Testing
- [18F]-AraG radiotracer, Chemotherapy, Radiotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Indiana University
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
This phase II trial is studying erlotinib hydrochloride to see how well it works in treating patients with advanced esophageal cancer or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT00045526
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a study to assess how much of the investigational drug, PF-00298804, is in the blood stream over a period of time (called pharmacokinetic tests or PK) in patients with locally advanced head and neck squamous cell…
- Trial name
- NCT01484847
- Testing
- PF-00299804
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Stage III Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy
A two-arm (two cycles' versus four cycles' capecitabine combined oxaliplatin concurrent radiotherapy) randomised Phase III clinical trial was started in Oct. 2015.
- Trial name
- DCOECRT (NCT02604615)
- Testing
- Capecitabine(Aibin), Oxaliplatin(Aiheng), Radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Squamous Cell Carcinoma
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants…
- Trial name
- NCT05319730
- Testing
- Paclitaxel, Irinotecan, Pembrolizumab
- Where
- 58 sites in United States, Brazil and 12 more
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Radical Trachelectomy for Women With Early Stage Cervical Cancer
The goal of this research study is to learn about quality of life, sexual functioning, and symptoms in women who have undergone abdominal radical trachelectomy for cervical cancer. This is an investigational study.
- Trial name
- NCT00813007
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Lung Cancer
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Conditions
- Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006036
- Testing
- cisplatin, lurtotecan liposome
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- NCIC Clinical Trials Group
Esophageal Squamous Cell Carcinoma
Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate safety and 2-year local control rate for extensive clinical target volumes in postoperative radiotherapy concurrent with chemotherapy for esophageal squamous cell carcinoma.
- Trial name
- ESO-Shanghai9 (NCT02916511)
- Testing
- Paclitaxel, Carboplatin, Radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Head and Neck Cancer
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent or metastatic head and neck cancer.
- Trial name
- NCT00062387
- Testing
- perifosine
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally…
- Trial name
- NCT04080804
- Testing
- Nivolumab, Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Dan Zandberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.